A photo of Jack Bleesing.

Jacob "Jack" J.H. Bleesing, MD, PhD


  • Co-Director, Diagnostic Immunology Laboratories
  • Associate Director, Immunodeficiency and Histiocytosis Program
  • Professor, UC Department of Pediatrics

About

MD: University of Leiden, Leiden, The Netherlands, 1989.

PhD: University of Leiden, Leiden, The Netherlands, 2002.

Residency: Pediatrics, University of Florida, Gainesville, Florida, 1993.

Fellowship: Allergy/Immunology, Duke University Medical Center, Durham, North Carolina, 1995.

Fellowship: Clinical Laboratory Immunology, National Institutes of Health, Bethesda, Maryland, 2001.

Interests

Immunobiology; translational research; immunologic methods development

Services and Specialties

Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, Leukemia, Hemophagocytic lymphohistiocytosisHLH, Rare Lung Diseases

Interests

Clinical investigation of primary immunodeficiency disorders (with emphasis on disorders of immuno dysregulation and B-cell disorders); immuno-reconstitution following blood and marrow transplantation; diagnostic immunology (with emphasis on flow cytometry)

Additional Languages

Dutch, German

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Clinical, immunological features, treatments, and outcomes of autoimmune hemolytic anemia in patients with RAG deficiency. Wang, C; Sun, B; Wu, K; Farmer, JR; Ujhazi, B; Geier, CB; Gordon, S; Westermann-Clark, E; Savic, S; Secord, E; et al. Blood Advances. 2024; 8:603-607.

Age Impacts Risk of Mixed Chimerism Following Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Non-Severe Combined Immune Deficiency Inborn Errors of Immunity. Fitch, T; Lane, A; McDonnell, J; Bleesing, J; Jordan, M; Kumar, A; Khandelwal, P; Khoury, R; Marsh, R; Chandra, S. Transplantation and cellular therapy. 2024; 30:101.e1-101.e12.

Posttransplantation late complications increase over time for patients with SCID: A Primary Immune Deficiency Treatment Consortium (PIDTC) landmark study. Eissa, H; Thakar, MS; Shah, AJ; Logan, BR; Griffith, LM; Dong, H; Parrott, RE; O'Reilly, RJ; Dara, J; Kapoor, N; et al. Journal of Allergy and Clinical Immunology. 2024; 153:287-296.

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Leiding, JW; Arnold, DE; Parikh, S; Logan, B; Marsh, RA; Griffith, LM; Wu, R; Kidd, S; Mallhi, K; Chellapandian, D; et al. Blood. 2023; 142:2105-2118.

Clinical Characteristics, Management, and Allogeneic Hematopoietic Cell Transplantation of Patients with Toll-like Receptor 8 Gain-of-Function Mutations. Arnold, DE; Kaviany, S; Aluri, J; Murguia-Favela, L; Wright, NA; Loughran, TP; Powell, J; De Ravin, SS; Rao, VK; Holland, S; et al. Blood. 2023; 142:936.

Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from the Primary Immune Deficiency Treatment Consortium. Thakar, MS; Logan, BR; Puck, JM; Dunn, EA; Buckley, RH; Cowan, MJ; O'Reilly, RJ; Kapoor, N; Satter, LF; Pai, SY; et al. The Lancet. 2023; 402:129-140.

Autoimmune Lymphoproliferative Syndrome (ALPS) Disease and ALPS Phenotype: Are They Two Distinct Entities?. Palmisani, E; Miano, M; Grossi, A; Lanciotti, M; Lupia, M; Terranova, P; Ceccherini, I; Montanari, E; Calvillo, M; Pierri, F; et al. HemaSphere. 2023; 7:e845.

Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency. Wang, C; Sun, B; Wu, K; Farmer, J; Ujhazi, B; Geier, CB; Gordon, S; Westermann-Clark, E; Savic, S; Ravishankar, S; et al. Blood. 2022; 140:2448-2450.

Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector. Pai, S; Nagarsheth, N; Prockop, S; Armant, M; Kohn, DB; Marsh, RA; Booth, C; Everett, JK; Bleesing, J; Chellapandian, D; et al. Blood. 2022; 140:10643-10645.

A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice. Schmitt, EG; Toth, KA; Risma, SI; Kolicheski, A; Saucier, N; Feliciano Berríos, RJ; Greenberg, ZJ; Leiding, JW; Bleesing, JJ; Thatayatikom, A; et al. JCI insight. 2022; 7:e162695.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

4.6
Overall Patient Rating